Insights · MedTech Adoption

Why Hospital Buying Outlasts Your MedTech Runway

A product can work and still struggle to win a hospital budget. Todd Dunn explains how risk, competing priorities and untested assumptions slow the path to a purchase.

MedTech · Stage 4: Proposal to Close · MedTech & Innovation

Short answer

How can a MedTech startup prepare for a hospital buying process that moves slowly?

Todd Dunn says startups must understand the hospital's clinical problem, financial constraints and approval process before pushing a sale. He recommends testing assumptions, building alliances across committees and funding the company for the real buying timeline. Value must also stand up against other demands on the hospital's time and money.

A working product does not guarantee a place in a hospital budget. Todd Dunn says MedTech teams can spend heavily on development and approval, then discover that the buying process will take longer than their plan allows. The next problem is understanding how the hospital decides.

Todd is founder and CEO of The Innovator's Journey. He spoke with host Terry Coutsolioutsos on the Zero Friction Podcast about experience as a MedTech CEO and inside healthcare systems. His advice starts with the buyer's risk, the assumptions behind a product and the other uses competing for a hospital's money.

Why does the hospital make buying so complicated?

Todd describes the process as complexity by design. He recalls asking a chief nursing officer and a chief operating officer whether the system had lost at least $5 million by investing on an untested assumption. The response was not whether it had happened, but how many times.

He uses a hypothetical 10 percent margin to explain the concern. A $5 million loss would require $50 million in revenue to cover it. The calculation is his illustration of why a health system may be cautious about another proposed investment.

His response to that caution is to do more homework. He tells MedTech teams to test their assumptions about the hospital's finances, problems and sources of friction. If the seller leaves that work to the buyer, it adds another burden to an already complex decision.

What timeline should the board be prepared to fund?

Todd gives an example of investors expecting an enterprise deal in six or nine months while the CEO believes the process will take 18 to 24 months. He says the business needs funding that reflects the actual path, rather than a shorter timeline the board wishes were true.

The hospital also wants confidence that the supplier will remain available. Todd says buyers need clinical and economic proof, but they also need to believe the company will still be there in three to five years. Adopting a product means investing the system's own time and money.

Pressure to close accounts too quickly can therefore create the wrong impression. Todd says the system may wonder whether a small company can handle an organization of its size. The selling plan and the funding plan both affect the confidence the buyer has in the supplier.

Who must agree before a relationship becomes a sale?

Todd distinguishes a relationship from an alliance. A relationship can open a conversation. An alliance forms around a shared clinical and financial problem. He warns against assuming that support from one doctor, even a chief medical officer, will produce a purchase.

He names value analysis, clinical governance, clinical appropriateness and IT governance as parts of the path. His practical question is which committees are involved and what criteria they use. The offer should help the system make its decision, rather than depend on a supporter to bypass it.

Todd prefers the hospital to pull its own data when defining the problem. He wants the seller and buyer working from an understanding the system recognizes. That makes the alliance more concrete than a general agreement that a technology sounds promising.

Which assumptions should you test before building?

Todd recalls engineers building a watch intended to remind nurses to wash their hands. The team considered technical requirements such as waterproofing. He asked a more basic question: what had to be true for the watch to deliver value?

The nurses had to wear it, and they had to be allowed to wear it. Todd says observations across four hospitals found problems with both assumptions. Younger nurses did not wear watches, some areas prohibited jewelry and the hospital leader would not buy the watches.

FDA doesn't build a business. It just builds approval.

Todd Dunn

He says those behavioral and contextual questions could have been tested before the watch was built. His broader method is to write down what the team believes, then design experiments to test it. That also makes it safer for people to acknowledge uncertainty instead of presenting assumptions as established knowledge.

What is the product really competing against?

Todd describes attending a capital allocation meeting in Charlotte and seeing a long list of requests. A colleague told him the money would run out after roughly 20 lines. The obstacle was not just the number of competing products in a category. The organization had more priorities than it could fund.

He names new ambulances and hiring nurses as possible alternatives to a proposed technology. A startup therefore needs to explain its value clearly enough to compete with other uses of the same time and money. Comparing features only with another device leaves that wider decision out.

Todd says discovery should establish the problem in its actual setting. People who would use the product and people who would buy it should both recognize the description. He recommends looking for the friction in the work and then understanding how that friction appears in the financial picture.

How do you define value the customer actually wants?

Todd contrasts asking why someone made a choice with asking what led to it and what criteria they considered. He says the latter can create a more open discussion. The aim is to understand the situation deeply enough to identify a meaningful change.

He calls that desired change a love metric. A customer might want a task to take two minutes, or want to leave work in time for a child's soccer game. Todd connects clinical, experience and financial measures to those desired outcomes.

He recommends showing the customer how the product delivers against those measures every quarter or twice a year. The measure then connects the initial discovery with ongoing value. For Todd, that work belongs in a plan the company can review and refine, so the team can tell whether its approach is improving.

Where this fits: stage 4 of the revenue funnel, Proposal to Close. Read what revenue friction is and how it is measured. See how RevRx AI works with MedTech teams.

Full episode transcriptAbout 14,500 words

From the episode captions, lightly cleaned. Speakers are not labeled, and the text may contain small errors. Time links play the episode from that moment.

0:00 Empathy, I think, is the heartbeat of healthcare when it's done well. But I also think if you can get to the love metric and you measure that and you show how your product is delivering to the clinical and experience love metric into the financial love metric. And if you can reflect that every quarter or twice a year to a customer, you win. You absolutely win. If you don't think the health care system's using AI against you when you're walking in the door, you're crazy. Hey there, I'm Terry Coutsolioutsos, founder of RevRx AI. We remove friction and architect revenue for MedTech and consumer health practices. Welcome to Zero Friction. This is Terry Coutsolioutsos and today I have a can'tmiss episode with Todd Dunn. He's the founder and CEO of The Innovator's Journey. And basically, you know, Todd and I came together on a call probably three or four weeks ago and really kind of discovered that we were both aligned around friction and removing frictions from the system. And so, we want to talk

About certain things today where we can help other leaders, whether they're in the health care side of the business or the provider side of the business, what they can do to remove friction from their particular systems. Todd has spent over a decade working on both sides of the fence. So, he's been a medtech CEO. He's also spent a lot of time working for providers in their systems and their transformational areas. He's also been mentored by the late Klay Christensen. He's a Harvard thinker and was behind a book called The Innovator's Dilemma and which has really kind of changed Todd's mindset and he has his own book coming out. So that system is a part of a book called The Innovator's Journey that's coming from Taylor and Francis coming out in November. And so what we want to talk about today is I want to get Todd to give us a little background on himself on how he got to where he's at and then we'll talk about like systems,

We'll talk about transformation and we will talk about removing friction from the system. So Todd, welcome to the program. Glad to have you here today. Hey, good to see you and thanks for the time Terry. I'm really looking forward to this dialogue. A little bit about me, I'll be quick. Grew up in the deep south. My dad was an entrepreneur, owned his own businesses, started them. So I learned frugality and hard work from him and he would always say we get paid last, which I thought was really interesting, right? And so it made me fiscally mindful even when I was in large systems like GE or Advocate or Intermount Healthcare. I've always been so mindful of being capitalally efficient. Just don't waste money. I got my masters, my MBA actually in supply chain management and spent the first half of my career really in an operating role between Cisco, McKessan and Seammens. But when I got to GE, I was in an operating role in a software division

2:50 That had a great partnership with Inter Mountain Healthcare. And during that time, I got to I met Klay Christensen. I started reading Steve Blank's work out of, you know, his four steps to the Epiphany and thought, "Oh, I kind of like this." And then I raised my hand one day at GE because I heard they're working on this innovation thing, Terry. And I emailed Beth Commtock at the time. She was the chief marketing officer. I said, "Hey, I'm raising my hand. I want to be part of this." She said, "Well, it's really a volunteer job." So I was okay with it. I had two roles at GE. And through that work, eventually it developed into what became known as GE Fast Works, their global innovation system. And I learned so much there because GE was like this the system darling, right?

Spread the language, methods, behaviors, measures of six sigma around the world when everyone kind of struggled with it. And so I thought what a great learning opportunity. I left there when we spun that division out of GE to merge with Microsoft. Joined Interm Mountain Healthcare innovation role for a long time. Then I went to Atumadvocate in an innovation role. Took a year off, wrote the book that you mentioned. That was a lot of fun. just really I just wanted to share what it was like inside of a company to try to create a transformation system. It's hard but I wanted to be very practical, something within reach that you could do Monday.

If you read the book over the weekend, you can go do something on Monday. And so I'm spending a lot of time now just not probably to the level that you are, but advising some medtech companies on how to really sell into health care systems, but also helping health care systems think through what is transformation, what should it look like now. I think we should be in version 2.0 probably after the learnings from the last 10 years. Live in North Carolina now. Love it. That's me, man. That's that's awesome. And you know, I think what's amazing about your career is that you've spent time on both sides of the fence. And when you talk about our audience, whether they're CEOs, founders, or commercial leaders inside the MedTech space, you've seen both sides. You've worked for the GMs, you worked for the Seamans, you've worked for the McKestins. These are monsters in the health care MedTech sector. And then you've worked for some of the most innovative health care

Providers in the country with Inner Mountain and Atrium Health who have really taken health care to a whole new level when it comes to transformation. So talk to me about what have you learned from working on both sides of the fence? Man, that could probably be a book, too. I I've learned, you know, I was a CEO of a medtech company. I'm going to try to articulate this in a way that I think is really important. systems that get you to clarity around the problem in context need to exist as an ongoing efforts. I think you've framed it as a framework of how an organization needs to think, how that needs to behave, the tools that they use to guide those behaviors and thinking or to test their own thinking.

5:49 And if you have a system, whether you're in a smaller MedTech company or a large behemoth, it makes it a whole lot easier to make really informed decisions around what is your definition of transformation? How do you do it? And if you're a MedTech company, how do you plug into that and resonate with a large health system that has at least a thousand things on their plate to do? That's one of my biggest insights was the need of a system. The other thing and I go back to this book by Amy Edmonson and it has just resonated with me forever. I think the name of her book is the fearless organization. If I remember I should remember this. It's one I've read it a few times. But the psychological safety to speak up and question the status quo.

Everybody needs the freedom to challenge the status quo because if they don't, just like 74% of those CEOs think their business is going to be out in 10 years. If you don't have a system that's coupled with the psychological safety of questioning the status quo, man, start playing them the ending of the music, right? And that I'm just a big believer in systems, established language. I'll give you a little number. It's fascinating. So when I started working for a large company, I wanted to get an understanding of how well they understood innovation. And so I decided to pick two questions. My first question was, if I were to ask a hundred leaders within this company their definition to write down their definition of business model and hand it to me, how many different answers would I get? And one of my fun colleagues, he said, 102. And I said, Jeff, I'm only asking a 100 people. He said, 'Yeah, but I got a couple of doctors that'll force you to take two because they're going to hedge

Their bets. I said, ' Okay, funny. Everyone told me that every answer would be different. And then I said, okay, in the last 60 days of those 100 leaders, how many of them have said or heard the term business model in a meeting? They said, "Oh, all of them." And so now you start to see the problem where there's a term being used because business models are the unit of competition as you know whether it's the portfolio of them or the individual one and you have leaders talking about it but they don't have the same definition. They don't have the same tools. They don't have the same approach to renovating, creating, or eliminating business models. And you're like, "Okay, there's inherently the problem." To your point, they lack the framework, Terry. And little questions like that to me are great assessments of whether or not you have a transformation system in place. So then I'll close with this. Imagine going on the floor. I used

8:20 To say, imagine I go on the floor. I'm on the fourth floor cardiac unit and I yell stat and I've got seven people, doctors, nurses, aps, therapists, and everybody has a different definition of stat. Let's say the doctor thinks it's 15 minutes. The nurse thinks it's one minute and I've got a patient who's coding and nobody's working together because definitionally they don't have the same clarity of how they can work together. That would never work in medicine. And so my point is it's the same with transformation in medicine.

Whether you're a large McCassen or a GE, a MedTech company or a health care provider, if you don't have a system with that unity around what transformation is, but then how do you do it? You have an episodic program versus building a DNA capability of transforming your company. And it could be a little company, 20 people, doesn't matter. You got to have it. You know, it's really interesting comment. I think that communication is usually the the main reason why people and teams succeed together and it's one of the main reasons why teams fail together 100% is being able to actually operate under common language and common understanding of that language. You use the word stat, you know, and that if there's five different meanings to the word stat, then that team is going to have a hard time aligning on what the goal is, right? M it's like if I say everything needs to be blue and there's five different shades of blue. I mean

Everybody needs to understand what when X is said this is what the common understanding is. So think about this Terry from a CFO perspective. Imagine you're the CEO and you walk into the CFO's office and you say hey show me the annual planning calendar please. And they don't have it or say show me how we define what is a capital expense versus a non- capital expense. you go into her office and she doesn't have a clear definition that matches one of her direct reports. That would never happen. It never happens in the financial world, in the clinical world. There's sepsis across the entire company. There are ways to do things.

And then you have this interesting thing called innovation, which I think is the verb. Transformation is the adjective or noun that you want. And there's like, wait a minute, you got the CFO rigger. You mentioned value analysis organizations earlier. They have templates. They have processes. You got the clinical world and then all of a sudden you get this innovation transformation world and it's kind of hit and miss. It's episodic in a lot of places. And I just believe that you can have the same type of scientific rigor and math rigor in that world that you have in the CFO world that you have in the clinical world that you have in value analysis committees. And the more you have it, the better off everybody's going to be.

11:06 You know, you mentioned something called psychological safety. And I love this word because, you know, I think change is a scary word. Transformation is a very positive word, but when the minute you start talking about change, you know, it's it's a scary word for most people. And so, we talk about psychological safety. You and I had talked about any type of evolution or transformation that organizations are trying to create, there's always 10% that will stand in the front of the line just because they love chaos and they love new things. And then there's 10% that are going to be at the back of the line that are never going to change. And so that's 20 that you don't have to really worry about either way. But there's 80% standing in the middle and they're thinking why, how much, what do I need to do, what's in it for me, you know, is it a good thing for me, is it a bad thing for me? So talk to me about like

Systems that promote psychological safety and what type of attributes do they bring to the table? Because I think this is a really interesting concept, right? For any leader out there trying to move from position A to position B, to me, I guess psychological safety would be a component that you need to model into a program to get that transformation to actually occur. Now, how would I build that? How would I build psychological safety into a system? So psychological safety could be systemic, not like sporadic, but it could be it could actually be an attribute that you could build into a system that would make it more consistent, more approachable, and more predictable for success.

That's a great question. I want to attack it from two angles if I can. I believe in this concept that you need to reward, give me a little southern levity, if you will, coins in the couch and dollars in the dryer. You want teams to find coins in the couch and dollars in the dryer at scale constantly and always on. And I articulate why I think that's a psychological safety thing. Sometimes we reward the big wins too much and we make that the safest way to promote a career. But if you have a structured platform and system, I call the program team salt that has a structured way of letting teams run challenges within their own team or with another team where they set their own destiny. It's like Dan Pink talked about mastery, autonomy, and purpose. But you got to put a system in place. It can't just be give me your good ideas. It still needs to follow the same logic of a problem with criteria and you fund it

13:40 With time or money if it hits the criteria. And so there are platforms, a few of them out there. We did this at Innermouth and Healthcare. We eventually designed it. They called it my voice. but where you give these teams the platform and the structure for questioning the status quo. And I could give you so many examples of where teams want the freedom to remove friction out of their day, like updating a database or something they hate doing. Put a system in place that gives them the psychological safety and the freedom to go fix things without having to go to the hill. Because those are the coins in the couch and dollars in the dryer that if you add them up over time over and over again, you create a culture of psychological safety and you start extracting time and money to reinvest somewhere else. I call it reinvestment innovation. And so that's one way you do it. The other way you can do it, there's

So many, but let's say that your business model is your unit of competition. So a team solve challenge is about a process or something at the team level. It's smaller. you own it within the sphere of your criteria, your team or with another team. You don't even need to know it. You just need to track it at the high level of the company. The other one is I think is you're going to laugh maybe is an activity I call an assumption burst. So goes back to medicine diagnose before you prescribe. But let's say you're doing a business model transformation and you're using a business model canvas from Alex Osterwalder. You have the teams write down we believe. Spend an hour writing down everything they believe and then you design the test and the experiments. It's a scientific method brought to innovation transformation.

But why? Like what causes me to be so passionate about it? If you make it part of a system that groups who want to renovate a business model or create a new one, they have to document their assumptions. You just made it safe for them to say, "I'm not sure." And then they run the experiment which resonates in healthcare, right? The scientific method is the root of great progress that you mentioned earlier. So you bring the principles of medicine into the principles of innovation and transformation and it makes it safe.

It's not safe to not diagnose if you're a doctor which basically leads I'm not really sure but I'm going to run a lab. You need to do the same with innovation transformation. Those are two ways to do it. Create a structure. I call the program team solve. Challenges is the structure. It's an expectation. It's a behavior. It's in your goals. And then if you're going to create or build a new business or renovate one, you have you've got all these assumptions and make it safe by making it part of the system for people to say, I know I have to go have evidence now, which intuitively you have to admit that you don't have it, but you got to make it safe. And that whole fail fast, fail cheap thing is a bunch of crap. You need to learn fast, learn cheap. And the way you do that is follow the scientific method. And that's all about writing down assumptions. That's the way I would

16:35 Do it. It's just this it it goes back to what you've been talking about, Terry. The system will elicit the behavior. And if the system elicits the behavior over and over again, that behavior becomes an organizational capability. And that's why I believe transformation can be a capability. But not without a system. So let's talk about transformation opportunity and let's talk about the opportunities for health care systems. I mean we're in the most I think the United States is one of the most innovative healthcare markets in the world in terms of I leading innovation and you know for years and years and years most of the new technologies were developed here now outside the US regatory authorities were a little faster to get things to market than the US but most of that innovation was built here I think when I talk to other commercial leaders whether they're small enterprise or large enterprise accounts getting new technologies into these health care systems has has become a totally different game. Okay.

And with the advent of value analysis committees and and listen I totally am behind the fact that every health care system should have a governance system of what's coming in their doors and what's being used and what's on formulary and what is good for their patients. I mean we are in health care so there needs to be some framework that says this is a good thing or this is a fit or it's not a fit. However, it seems like it's overdesigned. It seems like it's overengineered and it seems like it's designed with purposeful intentful complexity to sort of slow down innovation and transformation in some ways. Can you talk to me a little bit about that?

Complexity by design is what I like to call it. I agree with you and I understand it because I worked inside of a health system for so long. I was in a boardroom with a chief nursing officer and a chief operating officer eight years ago and I asked this question. Have we ever spent blown lost $5 million or more because we invested in something based on an assumption that we did not fit either validate or invalidate. The CNO leaned back. That's too painful to talk about. The COO said, "It's not have we ever, it's how many times have we done it." And if you do the math, if you blew $5 million and you had a 10% margin, which no health system does.

Mayo just bragged about 8.3, right? So, or didn't brag about it, they reported it, but they should be proud of it. But at 10%. You just blew $50 million in revenue to cover up $5 million. And so then you think, how many knee procedures or heart procedures did we have to do to bring in $50 million to waste on your bad idea? Okay. And so I think the complexity is there to stop that is to be so cautious because losing a dollar cost you 20 in a 5% margin perspective. And I think that's why, to your point, it's intentional complexity to make sure they're derisking every element of spending an extra dollar that they can because they've been burned so many times and it's it's just burned into their memories. And that's why I'm empathetic to it and I understand it. And it's also why I tell medtech companies, vet your assumptions about what you think the financials are, the problems are, the friction is for the health system. Don't put the burden on them. You need to do

20:13 Everything you can to understand every bit of that so that you can navigate the complexity more effectively. Yeah, that's a really good point and and I would say even 5% is generous for most health care systems in terms of return. Most of them are 2 3%. It's brutal. So think about that 5% you blew 5 million you had to generate a h 100red million in revenue and then Terry you dive into this and you you see the Affordable Care Act is going to pull back some of the extra Medicaid payments. Payers aren't giving you increases in payments that outrun inflation. So you literally almost can't make up the loss, right?

And you got to put a mechanism in place that stops the losses. And I think that's why you've got these committees that are so and they're multiple committees to your point. I think that's why they're in place, you know. So the message back to innovators of technology and introducers of new technology would be have your economic model ready. Have have your pure understanding of what friction you're doing to remove costs from the not just generating new procedures but possibly what are you doing to take costs out of the system. And then more importantly, how do you take risk out of the introduction of the new technology for them? Because the one thing I heard you say was so wise, you know, the risk the risk removing risk is because they don't have margin of error. They really don't have margin of error. And so their risk tolerance is almost zero, which is why there's such complexity to create the maze to get things in the door. So that's really a

Good a good a good thought process on when you're introducing new technology, taking risk out of the equation for the buyer. Again, you and I earlier talked about there's different perspectives of the table of there's a seller's perspective and a buyer's perspective. And you know, if you're not selling with empathy, you're not selling with a buyer's perspective. You're selling what's good for you and the company. You're selling features, you're selling benefits, you're selling speed, you're spelling deals, you're sp, you know, but on the other side is is what are you doing to bring value to the end user or the system or the patient or the stakeholder who's going to benefit from the technology. Man, that Terry, you're so right that and this is where I'll just be candid.

There's been a lot of talk, this is I think this is relevant. There's been a lot of talk about private equity and hedge fund money in healthcare, right? There are two camps. There's talk. It's real. I mean, it's it's it's there. There's there are two camps. People who think it's horrible for healthcare and people who think it's can be good. When I think about these MedTech companies selling into healthcare, I think one of the key friction points and you mentioned it, risk, empathy toward the customer, whether you're taking cost out or you're improving revenue because you've improved the procedure now they can do more of them without burdening the doctor even more. One of the frictions is the lack of understanding of a lot of venture firms and PE or hedge fund firms on that complexity that you brought up. And it may be tying it together in an odd way, but if you're if you have a CEO of a company of a medtech company, and you

23:34 Tell that CEO, we want that enterprise deal closed in 6 months, 9 months, and that CEO comes back and tells you this process is 18 to 24 months, and you need to fund it accordingly, and here's the path to it. If you don't accept that as an investor, you're probably going to have a really rough time building a company in today's healthcare system. Because to your point, Terry, the complexity of d-risking a decision, which is what I really think value analysis is for, it's a really key point and it needs to be there. If you don't figure out the whole path of a company from selling to solving to actual check and you think about it, you've got to let your CEO and your team have the psychological safety to tell you about the complexity of the health care system. And you can't just wish it to be six months or nine months because it's not going to be unless you're absolutely lucky. But it goes to that whole

Process. You got to have the clinical proof that it works. You got to have the economic proof that it works. But you got to have another angle on this. The health systems have to believe that you're going to be stable enough for them to invest their time and money that you'll be around in 3 to 5 years. This is not just about a oneshot thing and yeah, it's a great product. Nah, with all the consolidation, the health system has to believe that you're going to be around and it goes all the way back to your board. If your board's putting so much pressure that you're trying to convert these accounts too fast, then these health systems are going to get nervous and they're going to say, "Wait a minute. Is this company going to be able to handle something to the size that I, you know, that we are?" You know this from your days at Abbott? You know, you talk about integrating some of these small companies. Once you integrate

Them, a big health system is more confident in them because Abbott's behind them, right? It's a that that whole process to your point, that's all part of the complexity of selling into health systems. And I think early stage companies need to map out the complexity of decision-making. H how do these smaller companies partner with large health care systems when they do truly have innovation and they can bring something to the table but they you know just like they're asking for other investors and money to for for finding ways to bring that value. Are there ways for health care systems to invest in technologies too in a way that like you know if they see benefit in it like where they become a stakeholder too? Yeah, a number of these health systems have investment funds and those investment funds will only invest if they believe it's a clinical and business problem together that they can solve for. then they will invest. And there's nothing better than that, by the way. Getting a strategic on your cap

26:10 Table that believes in the problem and will talk about it publicly for you and with you is fantastic. And then the question becomes, what do I have to do to create that type of an alliance? And I think one of the most brilliant thinkers in the world is a guy named Michael Watkins. He wrote the first 90 days, master your next move. And in master your next move, he talks about this thing of relationships versus alliances. So I think a relationship can get you in the door. It can get you into a dialogue with a health system. An alliance around the problem clinically and financially can get you to a cell. And so at some point you have to realize that the relationship just buys you getting in.

But if you don't have it, you probably never will. If you violate it, you'll get kicked out. It's I mean it's a sacred thing, right? Because it's this currency of trust, but you have to create an alliance with the system. And so is there a code that the health system can use to pull all of the data where you can point to their problem? You sometimes you can buy definitive health care data. I'm not a I prefer the health system pull their own data. Sure. But to your point, you have to create an alliance with the health system and never get caught in the mistaken thing that one doctor like a chief medical officer can get you to a check. Like you can't. I wrote this thing called the seven deadly sins of healthcare startups. I wrote it 11 years ago. Some of it's still kind of true, but it's more complex now. But who do you need to get an alliance with? You brought up one of the most critical

Ones, the value analysis team. And then you got to go through clinical governance. You got to go through clinical appropriateness. You've got to go through IT governance. Yeah. Right. And so how do you create an alliance with those committees? And so I think what if I were a medical device company earlier, I would ask that question. If you never worked in a health system, you need to learn how decisions are made, which committees are involved, what criteria do they use, and then shape your offering to help the health system went hard.

So so so critical and I mean you know you talked about it earlier right? I mean you understand this stuff. You were you get it and health small companies really need to understand it and big health systems also need a playbook of how to engage the external world. Tell you a fun story. I love talking to you about it. When I was at Inner Mountain, I oversaw the healthcare transformation lab there. And our CFO, Bert Zimmerly, brilliant guy, such an innovative CFO, just a rare, rare guy. I was in his conference room office one day and my boss was there, Mark Propes, great CIO, and Bert looks at me and he says, "Hey, do you have a process for how you work with these smaller companies and how you make decisions?" I said, "Yeah, I do." And he said, "You do?" I said, "Yeah, I sure do. Do you want to see it? He said, 'Yes, I do. Cuz remember, he wanted me to be capitalally efficient. And I said, 'Well, when do you want it? One of the

29:13 Greatest statements ever in my career. He said, 'Isn't your office about 50 ft that way? I said, yeah. He said, well, if you have it, go send it to me now. I like. So, I walked to my office, emailed it to him. It was 43 lines. The first one I sent was 43 lines. That thing's almost 10 pages now. But here's my point. You need a playbook for how this works in a system because if not, you have this onslaught of all these early stage companies. If you don't have a problem list that you're trying to solve as an organization, if you don't have rules of engagement, first question is, do we have a contract with a large company that prevents us from working with this company? Just ask the question. Don't hope. Just ask the question. If the answer's yes, go to the next one. But you need a checklist that shows that you govern the onslaught.

Because you're right, there's so many great innovative companies, but if you don't have a playbook for how you engage the external world as a large system, you're disappointing the market and you're wasting internal time and money trying to field all of them. But you mention your framework. Well, and it's all about having, you know, there's a lot of remarkable technology out there that never gets seen because it listen, most small companies don't have the knowledge, number one, and number two, the bandwidth. I mean, just the work and the effort that goes into that value analysis committee process and dealing with 8.4 different stakeholders on every new technology offering. Yeah. you know, takes its own sales process by stakeholder. So, you know, it used to be, you know, I remember in the days when I first got into medical device sales, I literally would call a doctor and he'd say, "Bring it in." And I'd go to the hospital the next day and I might check in or I might not check

In. I might go right to the O or the Kath lab and bring my bag in and use one, two, three, four, five, 10 different things during the procedure. fill out my my invoice and have the the Kath lab manager or the O supervisor sign the paperwork, walk it down to procurement and collect the PO and I'd be on my way, right? Yeah. And and today, you know, you you can't get into a hospital system without going through a Reprax machine. You can't go into an O without getting a red hat put on your head. You can't, you know, and that's if you just get through the value analysis committee process, but now you have, that's right, you know, now you have not only a clinical stakeholder, you have a department stakeholder, you have procurement, you have finance, you have legal. If it's software, you're going to be dealing with IT. If it's software, you're going to be dealing with IT security. You know, you're going to

31:56 Might be dealing with, you know, some sort of chief medical officer or nursing officer, depending on what your product lines are. You have department heads. Then you have staff and stakeholders who you know training and all this stuff that that comes into new technology decisions. Small companies that's a tough road to hope. Let's just be like really really about that. That's a that's a big burden. And going back to some of our earlier conversation was, you know, the GPO framework might actually have you know a pathway for that that again most small companies don't want to give up anything on the pricing side and go to a GO but if there are innovation and new technology categories that GPOS can support and make it easy for hospital systems to adopt that might be an interesting angle to take. So tell me a little bit more about that opportunity. That's a great question Terry. When I think about a company, an image always comes to mind for me. Alex Osterwalder, one of the he's been one of Thinkers 50

For years, created this concept called a business model canvas. And so I think through the structure of a business model canvas and in two elements of that, there's what's your get, keep, and grow strategy. How do you get customers, keep them grow, but there's also this other really interesting one that's related. What's your channel to those customers? And to your point, early stage companies often worry about the tax of a Vizant or a premiere 3% tax, 5% tax, whatever it is. But I would remind them that's a channel because within Vizant, for instance, they have a breakthrough innovation category.

Premier has something that's they call very similar to that to where you submit your product into their process and they have customers who sit on their committees and review these technologies and they'll give it a stamp of a breakthrough innovation or not. But let's say that you get it and it's a breakthrough. Well, you just got the credibility of Vizant. What are they in 60some percent of the hospitals now? And Premier is probably right there. But that's a process in a committee that you don't get to present to, by the way, is you give their representative your content, you teach them about it, and they represent it for you. And so there's really this interesting currency of credibility that if you can make it through that and they say, "Yeah, this is a breakthrough innovation." Then by the way in like in September visiant has a day at their annual conference to where your product will get highlighted.

34:33 And the reason that I offer is your question provoked it is that don't overlook the credibility of a rigorous process that could stamp you as an innovative product and then all of a sudden that go becomes your channel a 5% cost channel to I mean look man hiring salespeople you know is really difficult and if you can use a channel to get into dialogues that only cost you 5% when you sell something I mean it's free until you sell something and so I just think you can't overlook that in today's world because a lot of these large companies are quotes kind of outsourcing a lot of their work to Vizant or Premier just to say okay what should we even look at let's only look at Vizant's breakthrough innovation technologies this year you just quieted all the friction for a health system by going to Vizant Premier I don't know if the research group has it quite that way but I know advocates process is incredibly rigorous

They partner with premier with their go and of Of course, HPG. Man, if your board thinks you're going to make it through HPG in a year, you're you're board's smoking something. Yeah. And by the way, HCA reminds me of Hemingway's book, Old Man in the Sea, I think is what it was, you know, to where he goes out and he catches this really large fish and it gets eaten by the time he gets back. And you think, why not just stay close to the shore and catch some brim, right? And everybody wants HCA, but I would argue probably a bad place to start because they're so big. They're so complex. And to your point, can you really handle them? You got to be very careful as an early stage company who you handle. Reason I bring that up is a lot of those companies that use the GO like a premier or Vizant are sometimes a little bit smaller sometimes. And it could open up a channel to where you

Could start building an economic model and argument that you could use to go to the bigger ones. you just have a really clear strategy on what your geck and grow approach is, not just going to burn money. And they all and they all have different, you know, sort of value offerings to technology and suppliers, right? And I think, you know, HPG and HCA has always been looked at as the most vertically compliant organization. You know, once you got in, then it was a really good thing for you because then you're on a formulary that has a standard of care initiative and that makes it very very appealing versus sometimes these other systems are a little less vertically integrated. They have a little more flexibility around what they can use when they use it type of thing. and go I think but to your point using these channels as and guilty as charged you know not wanting to go take things to the go because you know

37:21 You didn't really understand the value proposition very well most small companies don't want to use a go because theoretically historically they've not offered a lot of value in terms of being able to do anything for you okay like I mean really make it happen that's the one thing about HPG and HCA is that once you're there they tend to push for you, right? They then they try to to perform on that basis where the other GPOs get things on formulary and and and allowed choice, right? And that's kind of where, you know, unless you have the infrastructure to do it. But most companies today, and I think this is what's really going to resonate with today's leadership, if if they can take anything from our conversation today, here's what I'd like them to walk is understanding that the go may not be it's going to get you to the other side, but the door will be open and allow you to get to the other side yourself where the door is not going to be shut. And so

Finding ways to befriend and create value for these GPOs with these new technology offerings where you can make them look good as well might be a really interesting pathway and and not to have this previous known notion of don't want to go there because I'm just giving away my money. All right? Because that's the thought process and at the end of the day you're going to you're going to end up discounting anyhow. So you're going to end up giving away the money regardless. So do it in a way where you're actually getting some value for it and maybe you can you can make that value analysis committee process a little more efficient or you know it's great advice Terry what is interesting to me now compared to maybe 10 years ago is to your point these GPOs are part of the system and they're becoming more intertwined I mean even look at Vizian like quality scores and all the things they do now they've expanded their tentacles into health systems very effectively in the design of a really good exchange of value. And

So to some degree, you just have to accept that that's the way it is now. And then you almost ask the flip side of the question. There are two ways to think about this. You brought up something where they worry about the 5% tax. But you give a pricing schedule through Vizant or through Premier, right? You say, "Okay, if you buy 0 to 10, it's this price or up to a,000, it's that price." So you kind of set it in a way that could protect you and you can build in that 5% fee somehow and you'll be fine. But then if I were to ask you say, "Hey, Terry, if Vizant could help you sell $5 million a year of your device or your solution, would you be willing to pay them after the fact that they brought the money in? Would you be willing to pay them 3% of that?" And you, well, bro, really?

40:00 Yeah. Every day you would pay it. And so I think it's the mindset of it is not what they're taking from you. Because if you just look at it on a line item in an Excel spreadsheet, they're taking something from you. But if you zoom out to your business model and you think about what are the channels, how do I get eyes on my product in a credible way and how do I get keep and grow without having a really expensive channel? I think they're I really think they're a great value to smaller companies. That's my experience and it really sounds like that's a really interesting pathway.

I think so. Let's pivot on a conversation here. Let's pivot on a topic. So, let's talk about like the pace at which hospitals actually buy and let's talk about you've been in I mean you're in the boardroom, you're a CEO. What's it like on the other side when you're watching these companies struggle like you know and they're burning cash and you know you're you're trying to like you finally have spent all your money getting something to market by the way. Yeah. Right. So you've you've spent money on innovating an idea. You spent money on developing a product from a manufacturing perspective. You spent money going through a regulatory process and now you're you're there. You're there.

Okay. And now now the run rates aren't happening the way we wrote it up on the PowerPoint deck and you know cash is burning, the capital's burning. What happens? Tell me like what happens when that clock and that cash start looking at each other. stress levels go up a magnitude of 20x, it's rotten. I think a lot of times companies are built on assumptions. I'll go back to that argument. We believe that if we do this, it'll work. And then I say, okay, do you really have to build it?

I'm going to give you I think maybe a story may illustrate this. When I was at Inter Mountain Healthcare, a nurse came to the transformation lab and this is right before I joined the transformation lab and said, "We need a watch or something to remind us to wash our hands." And so what do you think the engineers in the transformation lab did? They were there to innovate. So they built a watch. Built a watch 3D printed most amazing watch you've ever seen. It was smart watch before watches were smart. It knew if you had washed your hands in the right way that chip had been chain trained and so they built the watch. And then of course there was a financial analysis that said oh look at how many nurses are how many watches we could sell. Damn. And so then you sit around, you're saying, hm, what has to hold true for the watch to actually deliver clean hands. And so we got in

42:33 This room, this little this little circle. And I decided to use some of the learning that Steve Blank had taught me. He's a father of the lean starter movement. Came up with this concept, a leap of faith assumption. What has to hold true? And so I asked the team, I said, "Hey, look, I'm kind of new to the project, but what has to hold true for the watch to deliver value?" And so the engineers like, "Got to be waterproof." Yeah. Someone said, "It has to tell time." Yeah, maybe has to change colors when you've washed your hands, blah blah. It's like I don't think that's it. Like, what do you mean?

I actually believe they got to wear the watch. The leap of faith assumption is they have to wear the watch. The other leap of faith assumption is that they are allowed to wear the watch. So, in O, a NICU, a Piku, any type of ICU, you can't wear jewelry. Right. Right. The reason I bring up the story is that in the early formation of a company, you really need to do the assumption first because you may make it through FDA, but FDA doesn't build a business. It just builds approval. And so, vet those assumptions that you actually believe, especially behavior assumptions, context assumptions. Write those down, vet them, and you might not have to spend any money. We never had to build a watch. We didn't have to spend 30 minutes building a watch if we would have just walked the halls, which is what we did. four different hospitals watched walked the halls. Nobody, the young nurses didn't wear watches. The guy who ran the hospital wouldn't buy the watches and in areas you couldn't

Wear the watches. And so I think that example is something that organizations need to think about. But now when you get to the point, let's say you you got a great product. I sat in a room in Charlotte four years ago with the CFO's right-hand person and it was a capital allocation meeting and I was blown away because I'd sat in a number of those and I looked at the request Harry I was like my how are we going to get through this and my buddy said we're not we can't get through it. So what do you mean? He said Todd by the time we get down about 20 lines we're going to be out of money.

And so there was this whole prioritization process and he ran out of money. Why do I share the story? Early stage companies worry so much about who they're competing with. That's the wrong way to think about the world. You don't I don't care if you're competing with Medronic. I I don't care. What you're competing against is the allocation of time and money inside of a system. You may be competing against them buying new ambulances. You may be competing against them hiring nurses. And so what you have to figure out is where's the strike or whatever whatever is happening, right?

Exactly, Terry. So when that the reason that I shared is you asked me like what's the perspective? I've been the CEO of a MedTech company and I've sat inside those meetings and so you have to have this ruthless focus on articulating your value that's so clear that you could win out over a new ambulance, a new helicopter, whatever other requests are coming in and then you got attention units you're competing with. And so if you don't frame it to the clinical problem that you talk about and the business problem and how you make it safe to buy, you really have to think like a system thinks versus thinking like a startup. Oh, we're going to sell this. We're going to exit for $200 million. Stop thinking that way.

45:45 Document how the system thinks and then pray to God that your board believes you. And what's the best way? I have I have my thoughts on this but so now we're sitting here trying to create the value proposition stakeholders. Yeah. But there is many things that comes in front of before you even begin to do your value proposition before you do your proposal before you align my product does here's your five problems and here's my five solutions and they all line up. Right. Right. Yeah. What do great innovators of technology and these startup companies need to do before that even happens? Is it a discovery process? Is it like landscaping? Like what do they do to take inventory of all the things that are necessary to be to help you be successful when it comes to the value alignment meeting? Like who do you talk to? When do you talk to them? What what types of information should you be seeking out that put you in a position

To be successful? You worked with Abbott, you know this because even your question alluded to it a little bit. So I had the fortune of knowing Klay Christensen and I remember he told me one day and he and his brilliant partner in crime and thinking, a guy Bobby Mesa said, "Think about the movie." The reason that I say that is that if you don't understand the friction in context that is caused by the absence of your product like why do current solutions fail? Well, what friction is caused because you're not there? The current products do what? I believe that you have to be able to articulate the problem in context in a way that the people who will eventually use your product in context would agree with and the people who would buy it would agree with it. And so you've got to spend you mentioned the word discovery. Be an archaeologist of the problem. I almost think about it as brainstorming. So many early stage

Companies get into brainstorming. throw that away for a little while and just go search for friction. Go search for the friction in context and then the friction in the P&L caused by the friction in context cuz right you know this your your podcast is just so articulated so well friction friction radiates friction radiates for burnout. Friction radiates on the P&L and so go understand that friction and design your product and your business model to remove it. If you do that homework really, really well and you're willing to hear things you don't want to hear, but that are true and facts, you're going to be far ahead versus just believing your idea is going to solve a problem that nobody really believes.

48:28 Well, it's a difference between, you know, h having a hammer and running around looking for a nail, right? Yeah. Or or having a toolbox and actually, you know, understanding what your your your client needs. And I use a framework and I actually have built it into my AI systems for discovery processes for a sales process. And I use Keenan which is gap selling methodology which is all around understanding what the gap is and so where is the pain where is the friction um where is the heat coming from and not even talking about product in that call like that really is truly just taking inventory of you know from a health care perspective patient care patient process workflow financial implications you know human resource allocation whether it's training whether it's time, whether it's room turnover, efficiency, all these things that get that played into that.

And having the right framework and understanding to ask the right questions to put the customer in a psychological mindset, by the way, to be open with you as well because you also have to get them to admit there is pain and most people don't like to admit psychologically that they have pain. Correct. Right. So, you have to build a framework. You have to build a process. You have to be intuitive and asking and and bring empathy, not just questions to the table, but I understand that must be really painful. That must be really hard. I can understand why that's a challenge, right? Using that type of language provides freedom, more freedom for the for the customer to actually outline for you what is really going on. Because if you walk away from the meeting getting false information, your alignment's never going to hit. like your value and your pain point. They're going to get to a value analysis committee and be like that's really not a painoint and you're and you spent all this time trying to

Align to this and this and this and this and all of a sudden they're not hitting right. So that discovery process to me is the biggest part of actually aligning the value down the road. And if you don't do the discovery I promise you you're never going to align on the value and it's never going to connect anywhere. And by the way now you have to do it eight4 times because you have 8.4 for stakeholders by the way. Right. You know what's interesting that you bring up made me think about a two concepts. A concept of why versus what in the way we ask questions. The second concept of this notion of a love metric.

51:05 So one of my favorite books is from a guy named Chris Voss. Never split the difference. Exactly. I use his methodology as well. Love his book. Yeah. And in some of his writings, whether it's in the book or I read his post, he talks about the problem of asking someone why. And so, for instance, why do you do it that way? If I were to ask you why did you choose to move to Florida, what's your first word? Typically, when someone asks you why, it puts you in a defensive mechanism number one. So, you're you're playing bingo. You play you say because as soon as someone says because, typically their dukes are up, man. in defensive mode to your point. But if I were to say, "Hey, it's cool you moved to Florida. What led you to the decision? What criteria did you use? What were you considering when you did that?" Then you're going to start talking and what you said made me think about this. You get in deep dialogue with them. And that's where you

Want to be because that's where the learning is. And don't be scared of that. And then you almost have to say, "Well, what would be good about that?" And the what would be good about that question leads you to the concept that a dear friend of mine taught me. His name is Roy Rosen called a love metric if we did this perfectly. This product worked perfectly for you. What would you love to have changed? And they may say, well, we know I didn't leave a device in a body. Or they may say, well, I would know that their stitches are not going to get infected. Whatever it is, I would love that. And they would say, well, what would be good about that? Versus asking, why is that important? What would be good about that? What would the measure of that be? What would that change for you once you leave the hospital? Well, I would get to go to my kids soccer games on time. The reason that I bring this up is you bring up

This word empathy. Empathy, I think, is the heartbeat of health care when it's done well. But I also think if you can get to the love metric and you measure that and you show how your product is delivering to the clinical and experience love metric and to the financial love metric. And if you can reflect that every quarter or twice a year to a customer, you win. You absolutely win. and you'll create word of mouth. But the generic measures that we use today, man, they just don't work that well. And so to your point, go to the context and learn it so deeply that you know the language, the friction. You got to go see it, right? Cuz movement in an O, you've been in an O. You've watched people get frustrated and they didn't say a word and you're like, "Hey, what what just frustrated you?" Cuz you saw it. And then you got to ask the five what, not the five W's. And get alignment on the love metric. If our

53:38 Company delivers to you, what would you love to have changed? You get those metrics, you're like, "Okay, we can commit to those." Bingo. It takes time. It takes a patient board, but if you do it, you have longevity. And then I think you'll get an exit with a Metronic, an Abbott, a J&J. But without that unique approach, you kind of just a you're another person on a long list trying to get money and attention from a health system. And there's nothing unique about you. In the gap is the love metric.

That's a good point. In the gap there is the love metric. Yeah. Right. Because some things like hey that you got to close the gap. How do you close it? You got to give me something that I would love because the gap is I'm here I want to be there. But current state versus future state. Right. So you have current state versus future state. And that love metric is somewhere in the middle where if I could do this would you love that? Right kind of element. That would close your gap. That would close your gap because sometimes the love metric is born out of understanding the friction takes too much time. Well how much is too much time? Well, what would you love? I would love it if I could do it in two minutes. Okay. I mean, if you I like how you frame it, Jerry. If you get in the dialogue long enough, empathetically get in the dialogue, you can learn what you need to learn to serve your customer and win.

The fundamentals of that will never go away. Authentically empathetic, too, is one thing. You know, it can't be can't be viewed as scripted. It can't be viewed as like, you know, they're just going through their list of questions for me. You really have to kind of, you know, take a challengers mindset of truly understanding the problem before you even walk in the door, right? Yeah. In some way so you can frame your conversation, have some sort of element of which takes intelligence, you know, and I think this is like for me, I use AI every day. I don't think most sales organizations are doing this. So there's a couple things that you mentioned. So I use Kenan's gap methodology for my discovery framework, right? Okay. Okay, I also use Voss, I use Jet Blunt, and I use another guy named Cloff and I program all that into my communication processes as well. And basic types of conversations that I'm having with my customers, the AI will actually pull out that relevance of that methodology and

Neuroscience and plug it into the communication piece and build these frameworks for that. And so like the whole game plan is is like if you're not using AI through these processes as well, you and I are talking about like how to use your brain a little bit, but like using AI to create an intelligence framework for yourself, using AI to build consistency around that framework and build a system with AI, right? plugging it into your communication channels and actually plug your AI in and teaching AI how to use these methodologies with your customers because they are effective. You don't have to remember to use them anymore.

56:29 You just tell the AI what you want out of it and it interprets the communication process and it builds it in a framework where then you have to use your mind too. You have to look at it. You have to scrub it. You have to make it your own. But it's there because I'm going to go in another avenue. If you don't think the health care system is using AI against you when you're walking in the door, you're crazy. They they already know what doctors are using what when they're using it. They already they've already laid up the competitive landscape of your technology versus the other five. And they already know the benefits across the board. They know the market shares. They know the preferences. and you're walking into I wouldn't even say I I used to say like as a device supplier we used to walk into gunfights with a knife. Right now I think we're walking into not just you're walking into an artillery battle with a

Knife these days and if you're not using AI to elevate yourself around intelligence of what's happening in their world and intelligence to actually helping you frame what's going on and actually testing yourself versus your competitors. By the way, like you know saying if I were the customer looking at this company and I used X Y and Z you can actually use AI to say this is what they're going to actually say about you. Yeah. You know what you boy what you're talking about now I believe that MedTech companies you're going to shoot me for this maybe maybe not I believe what you just mentioned is a service that MedTech companies should hire and the reason that I say it is that so comprehensive and if it gives you a direction and it doesn't work out a can do even do a premortem you could say hey we did this it didn't work tell me why and it has this incredible ability to analyze tens of thousands of factors in 10 minutes. As I think about startups,

Medtech companies to your point, if I ever did it over again, I would look for someone like you who I could say, "Hey, look, I really need to build a branding, communication, and marketing function, but I can't hire a quarter of million dollar marketer and I can't hire 10 salespeople for 200 grand because I have to be capitalally efficient. What should I do?" And I think that that service is, you know, you're going to arm 10 salespeople who could support five companies all supported by AI who understand the context of say Venus Access or something to do with a heart.

To me, that's the new model or it's that model should really become far more prevalent with MedTech companies than trying to hire the old traditional sales get on an airplane type model all the time. Like yeah, you were like the artillery thing, man. You're fighting You're fighting surveillance. Mhm. It's like you just and you can't afford it, man. I mean, I know of a company, Terry, that hired 20 something salespeople. Now, think about the expense of 20some salespeople who are all probably demand a base starting of 150 to go with an early stage company.

59:34 So, you're burning at least 3 million more, way more, plus 30% on top for benefits and expenses. and then add travel. It's even worse. Like I know someone the other day that flew from Tampa to Augustus and spent 1,500 bucks. But you think, okay, so that activity still needs to be done. Branding, marketing, communications, it still needs to be done. But now, what's the new way of doing it that prevents you from burning money and time that doesn't need to be burned, but getting to an insight way faster than you ever could? Sub agents. You know, if you're using claws, you develop out sub aents or whatever. But I I I think you're I think you're spot on and right on to something that I mean, you clearly know the industry incredibly well, but rethink your geting growth strategy and rethink it in the way that you're rethinking it. I think that's the future of MedTech companies. And I think investors are going to savvy up to this pretty quick. It's hard though because

Health care has always been a humanto human connection and that's you know it's it's hard to let go of you know the days in the O when you were representing but you know the mere fact is there's a couple things happening in the market. One is it's virtual meetings are easier to have number one. Number two is the new buyer does not appreciate humanto human connection the way a millennial or a Gen Z buyer does today either. So these guys want asynchronous relationships. They'd rather learn on YouTube. They'd rather learn 80% of today's buyer journey is done 80% digitally and 20% human contact. 20 years ago it was literally flipped. And so, you know, they don't prefer people, okay? They prefer to learn on YouTube.

They prefer to learn on an app. They prefer to do things differently. And so the bottom line is for these medical device companies, you have to figure out where to be, when to be, and how to be where your buyer wants you to be when how they want you to be. And that is harder today than ever, ever, ever before. You said something that made me I remember this movie so much. I was in an O when I worked for Atrium and this wonderful nurse, Christine Cis, she has her doctor now, Dr.

Hosted me to go into these OS so I could go learn. I wanted to go see how hemodynamics was managed and I was an internal guy. Remind I I led innovation there. I was an internal guy. So I'm in what I call the bunker. It's at the head of the bed where all the anesthesiologist sits and watch everything about you. And I'm at the head of the bed and there's an open heart, double valve replacement, heart's on bypass. Dr. Skipper, a wonderful human looks up at me. He said, "Who are you?" I said, "I'm Todd Dunn." He said, "I don't want to be rude, but what are you doing in my O?" And I said, "Dr.

1:02:18 Skipper, I work for the company. Christine hosted me. I'm just here to learn. I'm here to observe. I'm not here to talk." And he said, "Okay, I'm glad you came by to learn." He said, "Feel free to ask me questions. No problem." But I went into four other OS that day. Every single lead physician asked me what I was doing. This goes back to your point. The old way of going into OS and just walking in and thinking you're going to get to observe when you're an early stage company or an outsider.

People forget it's sacred. And I think it's getting more sacred because the onslaught of requests that these doctors and nurses have from all these companies. I think they just want to be in their O and do their job. They really do. Skipper was nice enough to me, but to your point, hey, go learn about it on YouTube. get on a video, learn to ask really good questions to try to put together the movie without thinking you need to go in a sacred space and learn it. That's hard. But I would also say, I think, Terry, that health care systems need to have people dedicated to doing ethnographic research on behalf of the company. Meaning your job is to spend time in the OS for the next two weeks.

You're in the OS's fulltime learning. You're a mouse in a corner. You're recording, you're writing down, and you're learning the friction in the O or in the transition to the floor, and you're going to come back and unpack it. And then we're going to have a problem list of things we're going to solve for, and we're going to go to the market, and we're going to go find the answer. And so then you you put this you you put this kind of control in place. But to what you're saying like the Keenan and all of that, that's the future of where this is going. health care systems are going to get more insular and if you don't do what you're saying, Terry, they're going to be a bunch of dead MedTech companies along the way that use the old model.

That's a shame because there's there's a lot of great technology out there that's just getting stuck, you know? Yeah. And by the way, think about like if let's say I call Jess said, "Terry, I got this med device company." Dude, I don't have money to hire 10 salespeople to cover the regions. Or if I just break the company into four regions, I don't have them. and I can't find them anyway because the really good ones are making great money and I can't hire them away. Can you help me develop out branding, communication, and marketing strategy and give me the insights that I need to do to shape my business model for a dime on a dollar compared to doing that? And you would probably say, "Yeah, I can do that." Right?

1:04:50 Think about how much time you just saved me. Well, it's and you build consistent patterns and you know, but I just know that there's a lot of things in today's marketplace where you know, venture capital and private equity want to come in and and offer tens of millions of dollars and there's certain stages when yeah, those owners aren't ready to go take that on. I mean, they don't want to become they don't want to become employees of another organization at that point. They they they started a company because they wanted to be a founder and an entrepreneur and they wanted to to run the show. And so, you know, but then there's that there's this gap being created today with money where, you know, if you need five or $6 million, that's probably the hardest chunk of change to go find because it's not growth capital. It's test capital, right?

And and and the reason that I separate the two, it's a great term, but it's a really great term. It's test capital because you're still trying to test how you build out a scalable, repeatable, profitable business model. Yeah. And to your point, 20 million's growth capital typically right now. Maybe when you get into some of these therapeutics, it's you're still doing heavy heavy research, but test capital needs to be the most capital efficient money that's out there. And if you're hiring salespeople for quarter of a million dollars a year and they're out in an airplane testing for you when a sub agent could do homework on the entire world for you in 30 minutes and find you people with the right here's the other thing too is it can actually find you know people with intent like it it it finds buyers with intent. There's so many signals in the marketplace that you can now use AI to say these group of people are interested in what you're doing, right? Which then allows you to

Engage with some sort of phone call or email and then allows you to qualify on the phone and allows you to have conversations focuses, right? And so that you're not wasting, okay, there's there's the $1,500, you know, flight from Tampa to Augusta, by the way. You probably have to go to Atlanta to do it. So you're probably spending six hours like you know 1 hour to drive the airport, an hour to wait at the airport, you know, an hour to fly and then another hour to wait and then another hour and then and then a rental. You've burned a whole day to like you know that's a trip that you might even go like is it better for me to even drive, right? So like you've it's not just the money that you spent but you've actually burnt time that you'll never get back in the world again by the way. So that's the one that's the one thing asset in the world that you cannot actually buy is time. It's once it's

1:07:23 Buried, it's gone. It's done. Right. Gone. Yeah. You just it man what you're saying I just keep thinking through the model. You're redesigning business models. It I mean I tell you this company 20some salespeople it blew so much money and and these are good people. I mean that that the sad thing about these are good people who are trying so hard to sell something. But imagine that company could have had five part-time people armed with the insights of AI sub agents telling them you should probably call that group in Spokane, Washington. They just posted something about their interest in this. Here's the person.

Call them. I mean you're like you're literally laser targeting. You're guiding the missile in. And I that's the way to do it because if not, you're really scattering so much money and time and you're just hoping that one of these things will land for you, but you I think about your measure. You're probably going to have a great measure for this. The cost of customer acquisition. Yeah. I mean, you're you're going to have a measure that says your old way used to cost you half a million. New way is going to cost you 50 grand in five months. I mean, you're Yeah. I love that model that you're talking about. It's got my brain turning.

Like you can find people who are interested in this topic but AI can find it for you. It can every day. It it does every day. Does in my business anyhow. And you should you should have this service for medtech companies. Well, it's kind of what I do. I mean that's part of what I do is I bring AI to medtech companies every day from an architecture perspective. But there's this new concept that I I think there's just talking to a lot of early stage companies that I know are struggling for like what do I need to what do I need to do to get this thing to market? They have approval. They have approval and they don't have the money to go hire 20 or 30 people. They just don't. And they don't.

And you got to go figure out and like one's not going to get it done. And you know, it's just like you've got to figure out where how can you go hire a partner that's going to help you get it done that knows the industry, not just the clinical side, but the business side, the CEO side, the value analysis committee side. I mean, there's all these complexities that get thrown in front of these small companies. And it's not just friction, it's inertia, too. It's it's there's just all sorts of, you know, things you've got to plow through that it's hard to be an early stage company. It's easier to listen making the product and and getting the idea and going to a manufacturer and getting it through the FDA used to be the hard part. Okay.

1:10:02 Not anymore. Not anymore. Like that is actually the easier part of the whole equation. The hardest part is now I have a privilege known. Now what? You know what's interesting, Terry? That part is so known now. Like I mean I even think AI could help speed that up. But of course it can. It's known like yep these suppliers in China do this. These suppliers in Costa Rica that you can find it. Here's the FDA book. You know it. Like oh but now how do I sell it?

How do I GTM? Go to market. It's a big thing. It's a big thing. It is so hard. I love that man. That's so brilliant. I mean, you're going to have some companies are going to win because you help them and they're going to and you know, part of it is you're going to buy them runway, too. I mean, money runs out. It runs out faster than most startups think it'll run out. But if you can buy them six months because they didn't have to hire big sales team, think about what you can do in six months now with that type of a of a digital team helping a really sharp person. So you take one fractional salesperson and you turn them into a team of 10 or or just work with GPOs and get value analyses started without a sales team yet. And that way you're not you mean you know because what you're going to deal with at a certain point in time is you know

You can use data that says okay here's the the 10 markets I should go after because these are where the procedures exist. Whether you use definitive data or IQVIA data or MedScout or you know MD, they all have data that says here's where I should go. Here's where not only from a hospital perspective, it'll tell you the doctor percentages of it's mind-blowing like you know who does what. So you can actually landscape everything out on paper. You can build your game plan. You can build a communication plan. you can digitally start engaging today, right?

Yeah. And then and then when you are ready to go, you've already mapped out a great deal of that process. You still have a lot of work to do, but at least you've got it mapped out and you can execute against it. So, anyhow, I know we're kind of deviating, but like I I just it's great. That's a great dialogue. Well, any other things today as we're kind of like wrapping things up here, Todd? What would be what would be one piece of advice you would give to a founder or a CEO of a MedTech company bringing something to market that truly has impactful value to a health care provider system? What's the one piece of advice? May I give two? You can have I'll give you one extra one. Sure. really understand if you have a board or even if you don't have a board, really understand the profile of who will be on the board. I cannot overemphasize the importance of that for your company and for your lifestyle. If your board wants

1:12:50 To meet with you every day, your board chair, you're probably in the wrong spot with the wrong board because that means they don't trust you. Don't trust you. Get out. The second thing I would say is exactly what you alluded to. Get a plan in place so that you can know if it's working or not. Because if you're just working your butt off and you don't have a plan that you can look at to see if you can refine or alter along the way, you don't really know if you're getting better as a company or not. Third thing I would say, I'll stop with three is rethink the models. See, search out expertise like yours because as a CEO, your your job is not to hire people. Your job is to grow the company. And so rethink methods of go to market, get, keep, and grow channels, but reach out to really rethink models based on where the world is today versus where maybe you want it to be or where

It was even two years ago. I would say rethink the model in the most capital and timeefficient way that you possibly can and test those models first. That's what I would do. Love that. And that's a mic drop, guys, on Todd Dunn as he finishes up the the podcast. I do have one more question for you, but it's a personal question. And so, if current day Todd Yeah. could go back to 22-year-old Todd coming out of college. All right. And I'm only going to give you one here. So, you don't get two and you don't get three. You're just going to get one answer. you can give younger Todd one piece of advice, whether it's professional, personal, financial, whatever it might be. What would that one piece of advice be?

Do a better job of patiently harnessing your irrassable attitude toward the status quo. Say that again. Be patient. Harnessing your irrassable attitude toward the status quo. Be patient. Be patient as you're trying to make things happen. Right. Yeah. Yep. Don't get frustrated. Stay true. Stay on the take a little longer. You kept harding hitting on it. It really brought to mind. Change takes time. Stay irassable with the status quo. It's the only way the world gets better. But also take a big breath. Be patient with it. If you think it's going to take three years, be okay if it takes you five.

Well, Todd, thank you so much. What a great day. I can't wait. I think we're going to get three episodes out of this one. So, I appreciate you being on and it was a lot of fun and I I really truly am better off after this conversation than when we started it. So, thank you. Me, too. You, man, you've got my brain cranking. I want to if we can find time over the next month about what you're doing inside of AI around those agents to find those insights. What you said is like, yeah, I can find people who care about what you're doing.

1:15:38 Like, what? I'd love to learn more for you because I've got I'm working on something interesting. And what you said was like bing, man. Dude, that medtech companies need what you're doing. They're just telling you it's that's the hardest damn thing about a medtech company is where do I target? What's my go to market efficiently as I can as fast as I can without hiring a bunch of people? Yeah. Good for you, man. Way to go. Good to see you. Good to see you too, Todd. Thank you.

Hey, thanks for the time, man. So, let's connect. Let's find where your revenue is getting stuck. Book a call at RevRx AI and build your revenue engine.

This article summarizes views shared on the Zero Friction Podcast. Statements are the guest’s own and are not medical, legal or regulatory advice.

Next step

Is this friction slowing your revenue?

Take the MedTech Revenue Scorecard or book a free Discovery Call.

Free 30-minute call: a commercial snapshot of your business (one strength, weakness, opportunity and threat, prepped before we talk) and your top priority fixes.